Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, . . . Alessandra Narcisi. (2024). Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: A 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis). Taylor & Francis Group.
Chicago Style (17th ed.) CitationLuigi Gargiulo, et al. Comparative Effectiveness of Tildrakizumab 200 mg Versus Tildrakizumab 100 mg in Psoriatic Patients with High Disease Burden or Above 90 kg of Body Weight: A 16-week Multicenter Retrospective Study - IL PSO (Italian Landscape Psoriasis). Taylor & Francis Group, 2024.
MLA (9th ed.) CitationLuigi Gargiulo, et al. Comparative Effectiveness of Tildrakizumab 200 mg Versus Tildrakizumab 100 mg in Psoriatic Patients with High Disease Burden or Above 90 kg of Body Weight: A 16-week Multicenter Retrospective Study - IL PSO (Italian Landscape Psoriasis). Taylor & Francis Group, 2024.